Article
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
The oncologist - 1 Jul 2020
Tzogani Kyriaki, Røshol Hilde, Olsen Helga Haugom, Aas Ida B, Dalhus Marianne Løiten, Håkonsen Gro Dahlseng, Nilssen Laila Sortvik, Lindberg Vibeke, Økvist Mats, Bolstad Bjørg, Rogovska Irēna, Karpova Natalja, Enzmann Harald, Gisselbrecht Christian, Pignatti Francesco
Abstract excerpt
On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms-like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor sign...
Topics
- Adult
- Aniline Compounds
- Humans
- Leukemia, Myeloid, Acute
- Multicenter Studies as Topic
- Mutation
- Pyrazines
- fms-Like Tyrosine Kinase 3